Brochure
26 Aug 2024
Cerbios FDF based on probiotic strain SF68
PDF 689 kB
Cerbios own and manufactures the strain Enterococcus lactis SF68 applied in different therapeutic areas:
- Diarrhea, travellers diarrhea and dysbiosis: drug with 20 clinical trials, CTD dossier and registration from Switzerland (for extra EU Countries)
- Acne & Seborrheic dermatitis
- Obesity/Cholesterol and metabiolic syndrome
- IBS
- Immunity Booster
Any product is supported by precilical and clinical evidences.
Cerbios business model if B2B, searching for commercial Licensees worldwide
Content provided by our supplier
Cerbios-Pharma SA
-
CH -
2015On CPHI since
-
3Certificates
-
100 - 249Employees
Company types
Primary activities
Other Content from Cerbios-Pharma SA (4)
-
Brochure High Potency Active Ingredients CDMO Services
Cerbios is highly qualified in process development of new APIs and HPAPIs for preclinical, clinical and commercial supply. Cerbios is the ideal and reliable partner for your New Chemical Entity (NCE), NDA submission and commercial manufacturing. -
Brochure Cerbios offers high quality tailor-made programs for biopharmaceuticals
From cloning to cGMP production, Cerbios meets your product development and manufacturing needs for recombinant proteins, monoclonal antibodies (mAbs) and novel mAbs derivatives including fragments and Bispecific. -
Brochure ADCs Toxin and Conjugation CDMO Services
Offered Services: Process and Analytical Development cGMP Manufacturing in the Fully Integrated site of Lugano Complete Regulatory Documentation for IND submission and NDA Commercial Supply